We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alternative-Splicing Database Launched in Europe

By Biotechdaily staff writers
Posted on 23 May 2003
A major European initiative in the post-genomics field highlights the importance of alternative RNA splicing, the mechanism that enables the cell to generate several distinct proteins from a single gene. More...
Called the Alternative Splicing Database (ASD), the initiative aims to build a unique human database of all the alternatively spliced genes to develop new diagnostic tools for major diseases such as cancer, neurodegeneration, and infertility.

The ASD brings together seven members from Germany, Spain, France, Israel, and the UK with complementary expertise and know-how. The consortium includes biologists involved in data collection and chip optimization and design as well as computer scientists working on data mining and user-friendly data interfaces. The ASD will run for three years. As part of the project, the data on alternative exons from human, mouse, drosophila, and rat that have already been published in peer-reviewed journals will be collected and integrated into a computer database that can be accessed by researchers and doctors. In addition, the ASD consortium will develop DNA microarrays that contain cDNAs of all the splicing regulatory proteins and their isoforms, as well as chips that incoporate a number of disease-relevant genomic signatures for cancer, neurodegeneration, and infertility. These chips will then be used to test an individual's predisposition and to diagnose these diseases.

"Not only will the ASD project allow us to investigate alternatively spliced variants associated with human diseases, but it will also enable study of the pathologic changes of factors regulating alternative splicing,” said ASD coordinator Dr. Stefan Stamm, of the Institute of Biochemistry, University Erlangen-Nuremberg (Germany). "This is of great importance in order to maximize the value of the large scientific initiatives such as the human genome and proteome projects.”




Related Links:
U. of Erlangen-Nuremberg

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.